Reward Functioning in General and Specific Psychopathology in Children and Adults.
CBCL
RDoC
comorbid psychopathology
reward
Journal
Journal of attention disorders
ISSN: 1557-1246
Titre abrégé: J Atten Disord
Pays: United States
ID NLM: 9615686
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
medline:
27
11
2023
pubmed:
21
10
2023
entrez:
21
10
2023
Statut:
ppublish
Résumé
Problems with reward processing have been implicated in multiple psychiatric disorders, but psychiatric comorbidities are common and their specificity to individual psychopathologies is unknown. Here, we evaluate the association between reward functioning and general or specific psychopathologies. 1,213 adults and their1,531 children (ages 6-12) completed various measures of the Positive Valence System domain from the Research Domain Criteria (RDoC). Psychopathology was assessed using the Child Behavior Checklist for children and the Adult Self Report for parents. One general factor identified Reward dysfunction is significantly associated with both general and specific psychopathologies.
Identifiants
pubmed: 37864336
doi: 10.1177/10870547231201867
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-88Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Authors: Ankita Saxena, Catharina A. Hartman, Steven D. Blatt, Wanda P. Fremont, Stephen J. Glatt, and Yanli Zhang-James declare no competing interests. In the past year, Dr. Faraone received income, potential income, travel expenses, and continuing education support and/or research support from Aardvark, Aardwolf, Akili, Atentiv, Corium, Genomind, Ironshore, Medice, Noven, Otsuka, Sandoz, Sky Therapeutics, Supernus, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, Arbor, Aveksham, Axsome, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, KemPharm, Lundbeck/Takeda, Shire/Takeda, McNeil, NeuroLifeSciences, Neurovance, Novartis, Pfizer, Rhodes, Shire, and Sunovion. He also receives royalties from books published by Guilford Press: